thalidomide-o-c-5-acid

Thalidomide-O-C5-acid is a chemically synthesized conjugate serving as an E3 ligase ligand-linker, combining the cereblon ligand derived from Thalidomide with a linker commonly used in PROTAC technology.

Thalidomide 5-fluoride (H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)-5-fluoro-) is a thalidomide-based Cereblon ligand that binds to the IRAK4 protein ligand via a linker to form PROTACIRAK4 degrader-1.

Thalidomide-5-OH (2-(2,6-dioxopiperidin-3-yl)-5-hydroxyisoindoline-1,3-dione) is the Thalidomide-based cereblon ligand that used in the recruitment of CRBN protein. It can be connected to the ligand for protein by a linker to form PROTAC.

Thalidomide-5-methyl is a Thalidomide-based cereblon (CRBN) ligand used for the recruitment of CRBN protein.

Thalidomide-O-CH2CONH-CH2COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based CRBN ligand and linker used in PROTAC technology.

Thalidomide-O-amido-C6-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate, integrating a Thalidomide-based cereblon ligand with a linker, suitable for PROTAC synthesis.

Thalidomide-O-amido-PEG2-C2-NH2 hydrochloride, incorporating an E3 ligase ligand and a linker, can be used as an immunomodulator for the treatment of cancer.

Thalidomide-O-amido-C3-NH2 TFA (Cereblon Ligand-Linker Conjugates 16 TFA) is a synthesized E3 ligase ligand-linker conjugate incorporating a Thalidomide-based cereblon ligand and a linker used in PROTAC technology.

Thalidomide-O-amido-PEG3-C2-NH2 TFA (Cereblon Ligand-Linker Conjugates 3 (TFA)) is a synthesized E3 ligase ligand-linker conjugate incorporating a Thalidomide-based cereblon ligand and a 3-unit PEG linker, used in PROTAC technology.

Thalidomide-O-amido-PEG2-C2-NH2 TFA (E3 Ligase Ligand-Linker Conjugates 24 TFA) is a synthesized E3 ligase ligand-linker conjugate incorporating the Thalidomide-based cereblon ligand and a 2-unit PEG linker, utilized in PROTAC technology.

Thalidomide-linker 9 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

Thalidomide-O-amido-C4-NH2 TFA (E3 ligase Ligand-Linker Conjugates 19 TFA) is a synthesized compound that functions as an E3 ligase ligand-linker conjugate.

Thalidomide-5-NH2-CH2-COOH (compound 114) is a selective inhibitor of the protomyosin receptor kinase and a ligand for E3 ligase, offering potential for studying various diseases.

Thalidomide-O-C6-NH2 hydrochloride (4-((6-aminohexyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione hydrochloride) is a synthesized E3 ligase ligand-linker conjugate.

Thalidomide-O-COOH (Cereblon ligand 3) is a Thalidomide-based Cereblon ligand utilized for recruiting the CRBN protein and can be linked to a protein ligand via a linker to create PROTACs.

Thalidomide-O-amido-C6-NH2 TFA (Cereblon Ligand-Linker Conjugates 11 TFA) is a synthesized E3 ligase ligand-linker conjugate comprising a Thalidomide-based cereblon ligand and a linker.

Thalidomide-O-amido-PEG-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate, incorporating a Thalidomide-based cereblon ligand and a linker. This compound is used in the synthesis of PROTACs.

Thalidomide-5-propargyne-NH2 hydrochloride, a Thalidomide-derived cereblon ligand, is utilized in recruiting CRBN protein and can be linked to a protein ligand via a linker to form PROTACs [for protein degradation].

Thalidomide-O-C7-NH2 is a synthesized conjugate compound comprising an E3 ligase ligand-linker conjugate. This compound incorporates a cereblon ligand based on Thalidomide and a linker that is commonly employed in PROTAC technology.

Thalidomide-5-CH2-NH2 (hydrochloride) is a Thalidomide derivative that acts as a cereblon ligand for CRBN protein recruitment. This compound can be linked to a protein ligand via a linker to form PROTACs.

Thalidomide-O-amido-C4-NH2 hydrochloride, a synthesized E3 ligase ligand-linker conjugate, combines the cereblon ligand derived from Thalidomide with a linker and is commonly used in the synthesis of PROTACs[1].

Thalidomide-O-amido-C8-NH2 hydrochloride is a synthetic conjugate of an E3 ligase ligand-linker, which combines a cereblon ligand derived from Thalidomide and a linker. It can be utilized in the synthesis of PROTACs[1].

Thalidomide-O-amido-C3-PEG3-C1-NH2 is a synthesized conjugate compound serving as an E3 ligase ligand-linker, featuring a cereblon ligand based on Thalidomide and a 3-unit PEG linker, specifically designed for use in PROTAC technology.

Thalidomide-O-PEG2-propargyl (E3 Ligase Ligand-Linker Conjugates 32) is a chemical compound that has been synthesized as a conjugate of an E3 ligase ligand and a linker. It incorporates the cereblon ligand based on Thalidomide, along with a 2-unit PEG linker. This compound is specifically designed for use in PROTAC technology, which utilizes ligand-induced protein degradation [1].

Deoxy-thalidomide-Pip-C-PIP-boc, a conjugate of E3 ligase ligand and linker, comprises Thalidomide and the corresponding Linker. It functions as a Cereblon ligand to recruit CRBN protein and acts as a crucial intermediate in synthesizing complete PROTAC molecules.

Thalidomide-5-NH-PEG1-NH2 hydrochloride is a Thalidomide-based cereblon ligand designed for CRBN protein recruitment. It facilitates the formation of PROTAC molecules by linking to target protein ligands, such as THAL-SNS-032, via a connector.

Thalidomide 5'-amine-alkylC6-amine serves as a specialized cereblon ligand for PROTAC research and development, combining an E3 ligase ligand and an alkylC6 linker with a terminal amine for target protein ligand conjugation. It is among a series of functionalized tool molecules designed for PROTAC R&D.

Thalidomide-O-C6-COOH is a synthetic conjugate that combines a Thalidomide-derived cereblon ligand with a PROTAC technology linker (E3 ligase ligand-linker).

Thalidomide-O-C8-NH2 is a chemically synthesized conjugate that combines a cereblon ligand derived from Thalidomide with a linker utilized in PROTAC technology. It functions as an E3 ligase ligand-linker conjugate.

Thalidomide-O-amido-PEG4-C2-NH2 is a synthesized conjugate combining a Thalidomide-based cereblon ligand with a (PROTAC) technology linker, acting as an E3 ligase ligand-linker conjugate to enable targeted protein degradation.

Thalidomide-O-C6-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate used in the PROTAC dTAG-13, a degrader of FKBP12F36V and BET[1].

Thalidomide-O-amido-PEG-C2-NH2 is a synthesized conjugate formulation designed as an E3 ligase ligand-linker conjugate, incorporating a cereblon ligand based on Thalidomide and a linker component commonly used in PROTAC technology.

Thalidomide-O-amido-PEG3-C2-NH2 hydrochloride, a synthesized E3 ligase ligand-linker conjugate, incorporates a cereblon ligand derived from Thalidomide and a 3-unit PEG linker. This compound is specifically designed for use in PROTAC technology, which utilizes small molecules to induce protein degradation [1].

Thalidomide-O-C7-acid is a compound synthesized as an E3 ligase ligand-linker conjugate, consisting of a cereblon ligand derived from Thalidomide and a linker commonly used in PROTAC technology.

Thalidomide-O-amido-PEG4-propargyl is a polyethylene glycol (PEG)-based linker used in the synthesis of proteolysis targeting chimeras (PROTACs)[1].

Thalidomide-O-amido-PEG3-C2-NH2 (Cereblon Ligand-Linker Conjugates 3) is an E3 ligase ligand-linker conjugate developed using a Thalidomide-based cereblon ligand and a 3-unit PEG linker, synthesized specifically for use in PROTAC technology.

Thalidomide-O-amide-C5-NH2 is a chemically synthesized E3 ligase ligand-linker conjugate, combining a cereblon ligand derived from Thalidomide with a linker commonly employed in PROTAC technology.

Thalidomide-O-PEG4-azide is a PEG-based PROTAC linker utilized in PROTAC synthesis[1].

Thalidomide-Piperazine 5-fluoride is a compound synthesized as an E3 ligase ligand-linker conjugate, incorporating a cereblon ligand derived from Thalidomide and utilizing a linker commonly employed in PROTAC technology.

Thalidomide-5-PEG2-NH2 hydrochloride, a Thalidomide-based cereblon ligand, is used for recruiting CRBN protein. It can be linked to a protein ligand via a linker to form PROTACs [1].

Thalidomide-5-O-C10-NH2 hydrochloride, a Thalidomide-based cereblon ligand, facilitates the recruitment of CRBN protein and, when linked to a protein ligand, forms PROTACs [1].

Thalidomide-5-O-C12-NH2 hydrochloride, a Thalidomide-based cereblon ligand, facilitates the recruitment of CRBN protein and, when linked to a ligand for protein, forms PROTACs [1].

Thalidomide-5-PEG6-NH2 hydrochloride, a Thalidomide-derived cereblon ligand, facilitates the recruitment of the CRBN protein and can be tethered to a ligand for protein conjugation via a linker to construct PROTACs [1].

Thalidomide-5-PEG2-Cl, a Thalidomide-derived cereblon ligand, serves as the ligand for the recruitment of CRBN protein. It can be conjugated to the protein ligand via a linker to produce PROTACs.

Thalidomide-5-O-C3-NH2 hydrochloride, a Thalidomide-based cereblon ligand, facilitates CRBN protein recruitment and can be conjugated to a protein ligand via a linker to synthesize PROTACs [1].

5-Maleimidovaleric acid, a cleavable linker for antibody-drug conjugates (ADCs) synthesis, is employed as an ADC linker[1].

Thalidomide-O-C8-Boc is a Cereblon ligand derived from Thalidomide, primarily employed in the recruitment of CRBN protein. This ligand can be linked to a protein ligand via a linker to create PROTACs.

Thalidomide-O-amido-PEG1-(C1-PEG)2-C2-NH2 is a synthetic conjugate that combines a Thalidomide-based cereblon ligand and a linker, commonly utilized in PROTAC technology. This compound serves as a connector between the target protein and the E3 ligase, facilitating targeted protein degradation.

Thalidomide-O-amido-CH2-PEG3-CH2-NH-Boc is a synthesized conjugate functioning as an E3 ligase ligand-linker, incorporating the cereblon ligand derived from Thalidomide and a linker, and is utilized in the synthesis of PROTAC BET degraders.